Commentary: Pharma's future is virtual,say Kate Moss and Dr Steve Arlington of PricewaterhouseCoopers
This article was originally published in Scrip
In its latest Pharma 2020: Virtual R&D report on the future of the sector, PricewaterhouseCoopers argues that incremental changes are no longer enough. Companies will need to decide what they want to focus on – whether, for example, to continue playing in a mass market or concentrate on developing speciality treatments. And whatever route they choose, they will have to make fundamental changes in the way they work.
You may also be interested in...
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
An upturn in M&A activity across the whole healthcare sector is expected in 2021, with the COVID-19 pandemic and the associated development of a vaccine shining a light on the sector, says a recent survey by Jefferies.
The European Commission has extended the indications for Janssen’s Tremfya to include psoriatic arthritis, and those for BMS’s Opdivo to include gastroesophageal cancer.